scholarly journals Humoral immune response following SARS-CoV-2 mRNA vaccination concomitant to anti-CD20 therapy in multiple sclerosis

2021 ◽  
pp. 103251
Author(s):  
Frederik Novak ◽  
Anna Christine Nilsson ◽  
Christian Nielsen ◽  
Dorte K. Holm ◽  
Kamilla Østergaard ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Immune Response ◽  
Humoral Immune Response ◽  
Humoral Immune ◽  
Anti Cd20

scholarly journals Humoral immune response after COVID-19 in multiple sclerosis: A nation-wide Austrian study

2021 ◽  
pp. 135245852110493
Author(s):  
Gabriel Bsteh ◽  
Sophie Dürauer ◽  
Hamid Assar ◽  
Harald Hegen ◽  
Bettina Heschl ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Immune Response ◽  
Humoral Immune Response ◽  
Antibody Testing ◽  
Seropositivity Rate ◽  
Humoral Immune ◽  
Austrian Study ◽  
Anti Cd20 ◽  
Disease Modifying Treatment ◽  
The Impact

Background: Knowledge on immunity after SARS-CoV-2 infection in patients with multiple sclerosis (pwMS) and the impact of disease-modifying treatment (DMT) is limited. Objective: To evaluate degree, duration and potential predictors of specific humoral immune response in pwMS with prior COVID-19. Methods: Anti-SARS-CoV-2 antibody testing was performed in pwMS with PCR-confirmed diagnosis of symptomatic COVID-19 from a nation-wide registry. Predictors of seropositivity were identified by multivariate regression models. Results: In 125 pwMS (mean age = 42.4 years (SD = 12.3 years), 70% female), anti-SARS-CoV-2 antibodies were detected in 76.0% after a median of 5.2 months from positive PCR. Seropositivity rate was significantly lower in patients on IS-DMT (61.4%, p = 0.001) than without DMT or immunomodulatory DMT (80.6%; 86.0%, respectively). In multivariate analysis, IS-DMT was associated with reduced probability of seropositivity (odds ratio (OR): 0.51; 95% confidence interval (95% CI): 0.17–0.82; p < 0.001). Predefined subgroup analyses showed marked reduction of seropositivity in pwMS on rituximab/ocrelizumab (OR 0.15; 95% CI: 0.05–0.56; p < 0.001). Rate of seropositivity did not change significantly over 6 months. Conclusions: Humoral immunity is stable after SARS-CoV-2 infection in MS, but is reduced by immunosuppressive DMT, particularly anti-CD20 monoclonal antibodies. This provides important evidence for advising pwMS as well as for planning and prioritizing vaccination.

Biomarkers related to the intrathecal humoral immune response as laboratory tools for multiple sclerosis diagnosis

2021 ◽  
Vol 429 ◽  
pp. 118168
Author(s):  
Sawsan Feki ◽  
Salma Sakka ◽  
Sabrina Mejdoub ◽  
Mariem Damak ◽  
Hend Hachicha ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Immune Response ◽  
Humoral Immune Response ◽  
Humoral Immune ◽  
Multiple Sclerosis Diagnosis

B Cell-Related Chemokine (CXCL13) in CSF is Correlated with the Intrathecal Humoral Immune Response in Patients with Multiple Sclerosis

2020 ◽  
Vol 37 ◽  
pp. 101569
Author(s):  
Sawsan Feki ◽  
Mariem Dammak ◽  
Sabrina Mejdoub ◽  
Saba Gargouri ◽  
Salma Sakka ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Immune Response ◽  
B Cell ◽  
Humoral Immune Response ◽  
Humoral Immune

scholarly journals Antibody response against HERV-W env surface peptides differentiates multiple sclerosis and neuromyelitis optica spectrum disorder

2017 ◽  
Vol 3 (4) ◽  
pp. 205521731774242 ◽  
Author(s):  
Giannina Arru ◽  
Elia Sechi ◽  
Sara Mariotto ◽  
Alessia Farinazzo ◽  
Chiara Mancinelli ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Immune Response ◽  
Neuromyelitis Optica ◽  
Humoral Immune Response ◽  
Serum Levels ◽  
Spectrum Disorder ◽  
Antigenic Peptides ◽  
Neuromyelitis Optica Spectrum Disorder ◽  
Serum Samples ◽  
Humoral Immune

Background A specific humoral immune response against HERV-W envelope surface (env-su) glycoprotein antigens has been reported in serum of patients with multiple sclerosis (MS). However, it has not been evaluated to date in patients with neuromyelitis optica spectrum disorder (NMOSD). Objective The objective of this paper is to investigate whether antibody (Ab) response against HERV-W env-su antigenic peptides differs between NMOSD and MS. Methods Serum samples were collected from 36 patients with NMOSD, 36 patients with MS and 36 healthy control individuals (HCs). An indirect ELISA was set up to detect specific Abs against HERV-W env-su peptides. Results Our data showed that two antigenic peptides, particularly HERV-Wenv93–108 and HERV-Wenv248–262, were statistically significantly present only in serum of MS compared to NMOSD and HCs. Thus, the specific humoral immune response against HERV-W env-su glycoprotein antigens found in MS is widely missing in NMOSD. Conclusion Increased circulating serum levels of these HERV-W Abs may be suitable as additional biomarkers to better differentiate MS from NMOSD.

scholarly journals VH4 Gene Segments Dominate the Intrathecal Humoral Immune Response in Multiple Sclerosis

2007 ◽  
Vol 179 (9) ◽  
pp. 6343-6351 ◽  
Author(s):  
Gregory P. Owens ◽  
Kimberly M. Winges ◽  
Alanna M. Ritchie ◽  
Sydni Edwards ◽  
Mark P. Burgoon ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Immune Response ◽  
Humoral Immune Response ◽  
Humoral Immune
Sign in / Sign up

Export Citation Format

Share Document